Piramal Pharma Limited has announced the schedule of an Analyst/Institutional Investor Meeting to be held on May 27, 2026, in Mumbai. The disclosure was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting is part of the 360 ONE Capital 16th Annual Investor Conference - Trinity India 2026. The nature of the meeting is described as a Group/One-on-one Meeting (Investor Conference). The venue for the meeting is Mumbai.

The company has noted that the dates are subject to changes, which may occur due to exigencies on the part of investors or the company. The intimation was signed by Maneesh Sharma, Company Secretary & Compliance Officer of Piramal Pharma Limited, on May 4, 2026.

Piramal Pharma Limited is listed on both BSE Limited with scrip code 543635 and National Stock Exchange of India Limited with symbol PPLPHARMA. The registered office of the company is located at Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India.

Meeting Details

The scheduled meeting represents part of the company's ongoing engagement with the investment community. The 360 ONE Capital 16th Annual Investor Conference - Trinity India 2026 provides a platform for analysts and institutional investors to interact with the company's management team.

Important Note

The company has explicitly stated that the meeting dates are subject to changes. Any modifications will be communicated as necessary, depending on exigencies that may arise from either the investors' side or the company's side.

Company Information

Piramal Pharma Limited operates with its registered office at Ananta Building, Piramal Corporate Park in Kurla (West), Mumbai. The company's corporate identification number is L24297MH2020PLC338592. For any queries related to the meeting, shareholders can contact the company at shareholders.ppl@piramal.com or call +91 22 3802 3000 / 4000.

Regulatory Compliance

The intimation of the meeting schedule is in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to disclose the schedule of meetings with analysts and institutional investors to the stock exchanges.

Stock Exchange Listings

The company's securities are traded on both major stock exchanges in India:

Piramal Pharma Limited has officially notified stock exchanges about the availability of its Q4FY26 financial results conference call transcript, ensuring continued compliance with SEBI listing regulations. The pharmaceutical company filed the updated notification with BSE and NSE following the transcript release on April 30, 2026.

Latest Regulatory Compliance Filing

The company submitted an official letter to both BSE Limited and National Stock Exchange of India Limited on April 30, 2026, confirming the availability of the conference call transcript. This filing was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in continuation of their earlier letter dated April 17, 2026.

Conference Call Documentation Access

Both the audio recording and transcript of the conference call discussing audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026, are now accessible on the company's official website. Stakeholders can access both documents at piramalpharma.com/financial-reports section.

Company Leadership and Authorization

The latest regulatory filing was digitally signed by Maneesh Sharma, Company Secretary of Piramal Pharma Limited. The digital signature was authenticated on April 30, 2026, at 14:31:29 +05'30', ensuring the authenticity and legal validity of the submission.

Corporate Information

Piramal Pharma Limited operates under CIN: L24297MH2020PLC338592 with its registered office located at Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India. The company maintains transparency through regular investor communications and compliance with all regulatory requirements.

This comprehensive documentation demonstrates the company's commitment to maintaining transparency and adhering to regulatory frameworks while keeping stakeholders informed about financial performance and corporate developments through multiple accessible formats.